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Abstract
Observational studies suggest that hematomas continue to enlarge during hospitalization in patients with
traumatic brain injury (TBI). There is limited data regarding factors associated with hematoma enlargement
and on whether hematoma enlargement contributes directly to death and disability in patients with TBI.
We analyzed data collected as part of the Resuscitation Outcomes Consortium Hypertonic Saline and TBI
Study. Hematoma enlargement was ascertained and collected as a predefined safety endpoint. We evaluated
the effect of hematoma enlargement on the risk of death and disability at 6 months based on the Extended
Glasgow Outcome Scale (GOSE) (dichotomized as >4 or ≤4) using stepwise logistic regression analysis.
We adjusted for age (continuous variable), admission GCS score (dichotomized at >5 and ≤5), and compu-
ted tomography (CT) scan classification (Marshall grades entered as a categorical variable).
Of the 1200 patients with severe TBI analyzed, 238 (19.8%) patients were reported to have hematoma
enlargement as an adverse event. The proportion of patients who reached favorable outcome at 6 months
was significantly lower (defined by GOSE of >4) among patients with hematoma enlargement (29.0% vs.
40.1%, p<.0001). The proportion of patients who died within 6 months was significantly higher among
patients with hematoma enlargement (31.9% vs. 20.7%, p<.0001). After adjusting for age, admission GCS
score, and initial injury score, the odds of favorable outcome was lower in patients with hematoma enlarge-
ment (odds ratio 0.7, 95% confidence interval [CI]; 0.5–0.97).
Our results suggest that hematoma enlargement may be a direct contributor to death and disability in
patients with TBI at 6 months. Future clinical trials must continue to evaluate new therapeutic interventions
aimed at reducing hematoma enlargement with a favorable risk benefit ratio in patients with TBI.
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Observational studies have suggested that intracranial
hemorrhage continues to enlarge in almost 30–42% of
patients with traumatic brain injury (TBI) [1–3]. The
risk of hematoma enlargement is higher in patients who
are studied early after occurrence of TBI [3]. In an
observational study, hematoma enlargement was
observed in 51% of the 63 patients with initial computed
tomography (CT) scan performed within 4 hours of TBI
[4]. Identification of factors associated with, or predic-
tive of, hematoma enlargement in patients with TBI may
be important to identify a group of patients who are high
risk, and in whom the risk benefit ratio of new therapeu-
tic strategies may be acceptable. Hematoma enlargement
appears to be associated with a high rate of neurological
deterioration in patients with TBI [5,6]. In a study of
171 patients, 54 (32%) suffered progressive brain injury
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due to enlargement of intracranial hemorrhages [7].
However, previous studies have been unable to conclu-
sively determine whether hematoma enlargement con-
tributes directly to death and disability or is a manifesta-
tion of severe TBI[3,7] and thus not an appropriate ther-
apeutic target.
We performed this study to address some of the afore-
mentioned issues regarding hematoma enlargement in a
prospectively studied cohort of patients with TBI.
Methods
We analyzed data collected as part of the Resuscitation
Outcomes Consortium Hypertonic Saline (ROC HS)
Trial Shock Study and Traumatic Brain Injury (TBI)
Study. The details regarding the trial have been pub-
lished previously [8]. Briefly, a multicenter, double-
blind, randomized, placebo-controlled clinical trial
involving 114 North American emergency medical serv-
ices agencies, within the ROC, was conducted between
May 2006 and May 2009. The study sought to determine
whether prehospital administration of 7.5% hypertonic
saline/dextran, compared to current standard therapy
with normal saline, as an initial resuscitation fluid,
affects survival following traumatic injury with hypovo-
lemic shock or severe TBI as manifested by a prehospi-
tal Glasgow coma score (GCS) of 8 or less. The study
was terminated by the data and safety monitoring board
after randomization of 1331 patients, having met prespe-
cified futility criteria. We included the TBI cohort in our
analysis, which included patients with blunt trauma, pre-
hospital GCS score ≤ 8, and age ≥15 years or weight
≥50kg. Patients with TBI, who met the criteria for hypo-
volemic shock, were included in the shock cohort.
Patients were randomized to a single dose 7.5% saline in
6% Dextran-70 (250cc), 7.5% saline (no dextran)
(250cc), or crystalloid (250cc) as the initial fluid for pre-
hospital resuscitation. In an effort to minimize variabil-
ity in the subsequent care of trauma patients, all sites
agreed to encourage the implementation of resuscitation
and critical care management guidelines, which included
clinical protocol for trauma resuscitation, transfusion
guidelines, intensive care unit (ICU) insulin infusion/
blood glucose control, sedation/analgesia protocol for
mechanical ventilation, mechanical ventilation protocol,
venous thromboembolism prophylaxis, protocol for ven-
tilator associated pneumonia, and management of severe
TBI.
This initial data, including demographics, mechanism of
injury, prehospital and emergency department (ED)
hemodynamic variables, time to definitive care, mode of
transport, injury severity score (ISS), the presence of
TBI, and total fluids in the first 12 hours were collected
prospectively as patient care progressed. Data collection
was based on a daily review of the medical records and
results of diagnostic studies. All in-hospital electrolyte
levels in the first 24 hours were tracked. Information
regarding the initial resuscitation of the patient, intracra-
nial pressure (ICP) monitoring and management, neuro-
logic assessment based on the GCS, and adherence to
the clinical care guidelines was collected. Serum sodium
values upon admission and every 8 hours for the first 24
hours were collected for all patients requiring ICU
admission. Any sodium value >160 mEq/L requiring
therapeutic intervention, any seizure activity associated
with hypernatremia, and any sodium values >
160 mEq/L without intervention, were considered seri-
ous adverse events. Total fluid and blood products
required in the first 24 hours and coagulation parameters
on admission were recorded for all patients. For patients
with TBI, the results of the first three head CT scans
obtained within the first week after injury were collec-
ted. ICP and cerebral perfusion pressure (CPP) at the
time of ICP monitor placement, total hours of ICP
>25 mmHg and CPP <60 mmHg (measured in incre-
ments of 15 minutes), and total amount of mannitol
administered in 12-hour period of time for the first 48
hours after injury were also collected. The time interval
between TBI onset and CT scan was estimated as the
sum of time intervals between 911 call and ED admis-
sion and between ED admission and CT scan.
Certain adverse events were collected as safety end-
points, which included evidence of increased intracranial
hemorrhage on head CT scan. All members of the
trauma team were instructed as to recognize the possible
adverse events prior to initiation of the trial and were
instructed to immediately report any suspected adverse
event to the investigators using an emergency contact
number. Any expeditable serious and life-threatening
adverse event was reported to the Food and Drug
Administration (FDA), Institutional Review Board
(IRB), and chairperson of the Data Monitoring Commit-
tee (DMC) within 72 hours by telephone, and by a writ-
ten report, submitted within 7 days. All nonlife-threaten-
ing unexpected serious adverse events were reported in
writing within 15 days. The main outcome measure was
six-month neurologic outcome based on the Extended
Glasgow Outcome Scale (GOSE) (dichotomized as >4
or ≤4) obtained by telephone survey. Additional neuro-
logical outcomes included disability rating score (DRS)
(at discharge and 6 months), and 28-day and 6-month
survival.
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We performed all analyses using the IBM SPSS 20 stat-
istical software (IBM Corp., Armonk, NY). Means and
frequencies were compared using one-way analysis of
variance and the [chi] [2] method, respectively. We eval-
uated the association of hematoma enlargement with the
patients’ demographic and clinical and laboratory char-
acteristics. Baseline variables of interest included age,
race, gender, initial systolic blood pressure (BP), admis-
sion GCS, baseline hemoglobin level, platelet count,
fibrinogen levels, and sodium levels. These variables
were dichotomized based on either median values (e.g.,
GCS score, serum sodium) or normal ranges (e.g., base-
line hemoglobin) to identify clinically meaningful cutoff
values for defining association.
We evaluated the effect of hematoma enlargement on the
risk of death and disability at 6 months based on GOSE
(dichotomized as >4 or ≤4) [9] using stepwise logistic
regression analysis. We adjusted for age (continuous
variable), admission GCS score (dichotomized at >5 and
≤5), and CT scan classification (Marshall grades II, III,
and mass lesion entered as a categorical variable) [10–
12]. Because our study cohort also included polytrauma
patients, we adjusted for ISS (dichotomized at >26 and
≤26) in the model [13–15]. A second multivariate analy-
sis was performed using death within 6 months as the
dependent variable and the model was adjusted for the
same potential confounding factors as mentioned above.
A p value below 0.05 was defined as an entry criterion
in each of the stepwise regressions. A p value below
0.05 was considered significant.
Results
Of the total of 1224 patients with severe TBI recruited in
the trials, 1200 were analyzed. Patients who died en
route (n = 4) and those who died on arrival to the ED (n
= 54) were excluded. The mean age (± standard devia-
tion [SD]) of the study cohort was 39±18 years and the
median GCS score was 3 (range 3). There were 238
(19.8%) patients who were reported to have hematoma
enlargement as an adverse event. The mean (95% confi-
dence interval [CI]) estimated time interval between TBI
onset and CT scan was 114 minutes (95% CI: 100–127)
and 130 minutes (95% CI: 116–144) in patients with and
without hematoma enlargement (p value = 0.26), respec-
tively.
The mean age (±SD) of patients who had hematoma
enlargement was similar in patients who underwent
hematoma enlargement compared with those who did
not have enlargement (39±17 vs. 39±18 years, p = 0.9).
There were no differences between the two groups in
regards to gender and race/ethnicity. The mean initial
systolic BP was higher in patients with hematoma
enlargement than those without hematoma enlargement
(146±30 vs. 140±30, p = 0.01). The proportion of
patients with admission GCS score ≤5 was higher
among patients who underwent hematoma enlargement.
The ISS was significantly higher among those who
underwent hematoma enlargement. The proportion of
patients with ISS score >26 was significantly higher
among those with hematoma enlargement. There was a
trend for mean fibrinogen levels to be lower among
those who underwent hematoma enlargement. There was
no difference in proportion of patients randomized to
hypertonic saline with or without dextran in patients
who had hematoma enlargement compared with those
who did not have hematoma enlargement. The propor-
tion of patients with diffuse injury types II and III, and
mass lesions on initial CT scans were higher among
patients who underwent hematoma enlargement.
The proportion of patients with best GCS ≤5 continued
to be higher among patients with hematoma enlargement
on Days 2 through 5 (Fig. 1). The requirements for ICP
monitoring, ventriculostomy, and craniotomy were
higher among patients with hematoma enlargement,
which was evident within the first 12 hours. The hours
of time spent with ICP>25 mm Hg, CPP<60 mmHg, and
the proportion of patients with serum sodium
>145 mmol/L within the first 12 hours was not different
between patients who underwent hematoma enlargement
compared with those who did not have enlargement. The
mean amount of mannitol used (g/kg) in the first 12
hours was higher among those who underwent hema-
toma enlargement. A significantly higher proportion of
Figure 1. The proportion of surviving patients with Glas-
gow Coma Scale (Gcs) score of ≤5 in severe Tbi patients
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patients required mannitol, additional hypertonic saline,
and hyperventilation within the first 5 days among
patients who underwent hematoma enlargement. The
amount of fresh frozen plasma, cryoprecipitate, and pla-
telets transfused were higher among patients who under-
went hematoma enlargement. There were significantly
higher rates of in-hospital adverse events, including
pneumonias, urinary tract infections, and overall noso-
comial infections, in patients who underwent hematoma
enlargement. The total ICU days and hospital days were
significantly higher, and ventilator free days were signif-
icantly lower among patients with hematoma enlarge-
ment.
The proportions of patients in DRS categories of moder-
ately severe/severe/extremely severe or vegetative/
extreme vegetative/dead were significantly higher
among patients with hematoma enlargement compared
with those without enlargement at both 1 month and 6
months. The proportion of patients who reached favora-
ble outcome at 6 months was significantly lower
(defined by GOSE of >4) among patients with hema-
toma enlargement (29.0% vs. 40.1%, p <.0001). The
proportion of patients who died within 6 months was
significantly higher among patients with hematoma
enlargement (31.9% vs. 20.7%, p<.0001). After adjust-
ing for age, admission GCS score, and initial trauma
score, the odds of favorable outcome was lower in
patients with hematoma enlargement (odds ratio [OR]
0.7, 95% CI; 0.5–0.97). After adjusting for age, admis-
sion GCS score, and initial trauma score, the odds of 6
month survival was not significantly lower in patients
with hematoma enlargement (OR 0.9, 95% CI; 0.6–1.2).
Discussion
In our cohort of severe patients with TBI, hematoma
enlargement was observed in 20% of the patients who
survived prehospital resuscitation. The proportions of
patients in DRS categories of severe, vegetative and
dead were significantly higher among patients with hem-
atoma enlargement at both 1 month and 6 months. The
rate of favorable outcomes and survival at 6 months was
significantly lower among patients who underwent hem-
atoma enlargement. It is possible that hematoma
enlargement was a manifestation of severe TBI and
higher rates of death and disability are related to severity
of initial TBI. In such circumstances, preventing, or
ameliorating, hematoma enlargement is unlikely to
reduce the death and disability associated with TBI. We
Table 1. The association of hematoma enlargement with the patients’ demographic, and clinical and labora-










Overall number (%) 962 238








African American 93(9.7) 12 (5.0)
White 489(50.8) 114(47.9)
Other 12(1.2) 3(1.3)
Hispanic or Latino 19 (2.0) 7(2.9)
Randomization group
0.1
Hypertonic saline/dextran 279(29.0) 56(23.5)
Hypertonic saline 260(27.0) 60(25.2)
Normal saline 423(44.0) 122(51.3)
Out-of-hospital GCS (median, range) 5±2 4±2 0.4
Out-of-hospital GCS >5 421(43.8) 11(4.6)
0.08Out-of-hospital GCS ≤5 399(41.5) 149(62.6)
ISS, (median, range) 24±16 33±12 <.0001
ISS >26 368(38.3) 151(63.4)
<.0001ISS ≤26 575(59.8) 85(35.7)
Marshall Score, first head CT scan
<0.0001
Diffuse injury I 366(38.0) 6(2.5)
Diffuse injury II 319(33.2) 114(47.9)
Diffuse injury III 101(10.5) 44(18.5)
Diffuse injury IV 31(3.2) 12(5.0)
Mass lesion 132(13.7) 59(24.8)
Others 12(1.2) 3(1.3)
Out-of-hospital advanced airway 573(59.6) 151(63.4) 0.3
Time from dispatch call to fluid administration, min (mean±SD) 35.0±23.6 34.7±22.5 0.9
Total out-of-hospital time, min (mean±SD) 57.1±29.4 54.8±27.3 0.3








Abbreviations: CT, computed tomography; GCS, Glasgow Coma Score; ISS, Injury Severity Score; L, liters; min, minutes; Range for GCS, 3 through 15;
range for ISS, 0 through 75; SD, Standard deviation
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performed multivariate analysis to adjust for known pre-
dictors, such as age, admission GCS score, admission
ISS, and CT scan findings. Hematoma enlargement
reduced the odds of favorable outcomes at 6 months,
independent of the known predictors of 6-month out-
come in patients with TBI. Therefore, it appears that
hematoma enlargement directly contributes to death and
disability among patients with TBI. Our ability to con-
clusively demonstrate the relationship between hema-
toma enlargement and 6-month outcome is related to the
large sample size and high compliance with the 6-month
follow-up assessment. Previous smaller studies have
supported our conclusions. Oertel et al.,[3] in a study of
142 patients with TBI, reported that 17% of patients
Table 2. The association of hematoma enlargement with in-hospital physiological parameters, therapeutic
interventions, and adverse events in patients with severe TBI.
 
Patients without hematoma enlarge-
ment
 




Overall number (%) 962 238
Admission physiology
Admission systolic blood pressure, mmHg (mean±SD) 140 ± 30 146 ± 30 0.01
Admission systolic blood pressure ≤140 mmHg 499(51.9) 106(44.5)
0.04Admission systolic blood pressure >140 mmHg 463(48.1) 132(55.5)
Admission systolic blood pressure ≤90 mmHg 49(5.1) 9(3.8) 0.4
Admission GCS (median, range) 3 ± 4 3 ± 3 0.002
Admission GCS >5 334(34.7) 61(25.6)
0.007Admission GCS ≤5 625(65.0) 177(74.4)
Hemoglobin g/dL (mean±SD) 12.8 ± 2.2 12.6 ± 2.2 0.4
Admission INR (mean±SD) 1.2 ± 0.5 1.2 ± 0.4 0.6
Admission serum sodium, mEq/L (mean±SD) 143 ± 5.8 142 ± 6.1 0.05
Serum sodium >145 mEq/L
At 0–4 h 361(37.5) 82(34.5) 0.3
At 4–12 h 222(23.1) 76(31.9) 0.1
At 12–24 h 173(18.0) 72(30.3) 0.01
First ED platelet count (mean±SD) 237660 ± 72316 236770 ± 70542 0.9
First ED fibrinogen level, mg/dL (mean±SD) 227.4 ± 102.6 205.5 ± 72.8 0.06
Neurologic monitoring
ICP monitored 207(21.5) 146(61.3) <.0001
Initial ICP, mmHg (mean±SD) 16±15 19±14 0.1
Initial ICP ≥25 mmHg 32(3.3) 31(13.0)
0.1Initial ICP <25 mmHg 152(15.8) 97(40.8)
Highest ICP in the first 12h, mmHg (mean±SD) 23±19 27±18 0.05
Highest ICP ≥25 mmHg in first 12 h 64(6.7) 63(26.5)
0.02Highest ICP <25 mmHg in first 12 h 139(14.4) 82(34.5)
Hours with ICP >25 mmHg in the first 12 h (mean±SD) 0.9 ± 2.6 1.3 ± 2.8 0.1
Initial CPP, mmHg (mean ± SD) 73.9 ± 22.3 72.2 ± 20.3 0.5
Initial CPP ≥60 mmHg 142(14.8) 82(34.5)
0.3Initial CPP <60 mmHg 35(3.6) 28(11.8)
Hours with CPP <60 mmHg in first 12h (mean±SD) 1.6 ± 3.0 1.8 ± 3.1 0.5
Interventions for intracranial hypertension
Total mannitol in first 12 h, g/kg (mean(95%CI)) 5.5(2.4–8.6) 12.4(7.5–17.4) 0.01
Mannitol in first 5 d 152(15.8) 99(41.6) <.0001
Additional hypertonic fluids in first 5d 82(8.5) 54(23.9) <.0001
Hyperventilation
First 24 h 10(1.0) 13(5.5) <.0001
First 5 d 15(1.6) 13(5.5) <.0001
Ventriculostomy
First 24 h 75(7.8) 73(30.7) <.0001
First 5 d 80(8.3) 80(33.6) <.0001
Craniotomy
First 24 h 83(8.6) 71(29.8) <.0001
First 5 d 88(9.1) 79(33.2) <.0001
In hospital management
Intubated in ED 280(29.1) 91(38.2) 0.006
FFP (mL) given (mean(95%CI)) 217.7(177.8-257.6) 416.0 (295.7-536.4) <.0001
Cryoprecipitate (mL) given (mean(95%CI)) 8.0 (5.0-11.0) 18.2(7.4-29.0) 0.01
Platelets (mL) given (mean(95%CI)) 39.9(27.0-52.7) 96.9(58.0-135.7) 0.001
Total Fluids in First 24hrs, L (mean±SD) 6.5±5.4 8.2±5.7 <.0001
Adverse events
≥1 Nosocomial infections 235(24.4) 101(42.4) <.0001
Pneumonia 168(17.5) 73(30.7) <.0001
Bloodstream infection 44(4.6) 19(8.0) 0.05
Urinary tract infection 66(6.9) 27(11.3) 0.04
Wound infection 19(2.0) 13(5.5) 0.005
Hypernatremia (sodium >160 mEq/L) requiring intervention 25(2.6) 12(5.0) 0.05








Abbreviations: CI, confidence interval; CPP, cerebral perfusion pressure; d, days; ED, emergency department; FFP, fresh frozen plasma; GCS, Glasgow
Coma Score; h, hours; ICP, intracranial pressure; INR, International normalization ratio; SD, standard deviation
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with hematoma enlargement and 28% of patients with-
out hematoma enlargement had a favorable neurological
outcome at discharge (p = 0.13). Six-month follow-up
data were obtained in only 51% of patients. At 6
months, a favorable neurological outcome was seen in
60% of patients with hematoma enlargement and in 70%
of those without hematoma enlargement, respectively (p
= 0.34). Narayan et al.,[4] in a study of 64 patients,
reported that 7 of 35 (20%) TBI patients with hematoma
expansion and 1 of 25 (4%) TBI patients without hema-
toma expansion died.
The most likely explanation is that the higher death and
disability was due to secondary neurological injury
among those who underwent hematoma enlargement.
The proportion of patients with GCS score ≤5 remained
greater over each successive day, postadmission, among
those with hematoma enlargement. The requirement for
mannitol, additional hypertonic saline, and hyperventila-
tion was higher within the first 5 days among patients
who underwent hematoma enlargement. Such observa-
tions suggest a higher rate of secondary neurological
injury among those who underwent hematoma enlarge-
ment. The higher proportion of in-hospital adverse
events such as nosocomial infections may have contrib-
uted to increasing the rate of death and disability among
patients with hematoma enlargement. Our observations
are similar to the study by Oertel et al.,[3] which repor-
ted that the proportion of patients with mean daily ICP >
20 mmHg was higher in those with hematoma enlarge-
ment compared with those without hematoma enlarge-
ment. Previous investigators also reported that patients
who undergo hematoma enlargement have larger hemor-
rhages and a higher frequency of subdural hemorrhages
and/or subarachnoid hemorrhages on initial CT scan
[4,16]. This may further predispose such patients to the
exaggerated detrimental effect of increase in intracranial
mass effect, due to limited intracranial compliance.
Previous studies have not been able to identify consis-
tent predictors of hematoma enlargement [2]. Patients
who undergo early CT scan after TBI are more likely to
undergo hematoma enlargement [1,3,4,7], although
some studies including ours have not confirmed this
observation [2]. We observed that GCS ≤5 and ISS ≤26,
at admission, were associated with a higher rate of hem-
atoma enlargement. The relationship between lower
GCS and hematoma enlargement in patients with TBI
was also identified by Chieregato et al [16]. Large size
intraparenchymal hemorrhages, subdural hemorrhages,
and/or subarachnoid hemorrhages on initial CT scan
appear to be associated with a higher risk of hematoma
enlargement [4,16]. We observed that the pattern of
injury on initial CT scan (categorized by the Marshall
classification) was associated with a risk of hematoma
enlargement similar to a previous study [16]. Elevated
international normalized ratio (INR) or D-dimer concen-
trations were associated with hematoma enlargement
[7]. Similar to our study, other studies have not been
able to demonstrate any relationship between laboratory
measures of coagulopathy and hematoma enlargement
[2]. However, patients who underwent hematoma
enlargement in our study were more likely to receive
fresh frozen plasma, cryoprecipitate, and platelet trans-
fusions presumably to prevent further enlargement once
CT scan evidence of hematoma enlargement was detec-
ted. Furthermore, we wanted to study the effect of
hypertonic saline, which has become a commonly used
agent in the treatment of severe TBI, [17–20] on hema-
toma enlargement. Hypertonic saline decreases platelet
function, impairs the integrity of the plasma coagulation
system, [21,22] and may increase the rate of hematoma
Table 3. The association of hematoma enlargement with outcome measures in patients with severe TBI.
 Patients without hematoma enlargement
 




Overall number (%) 962 238
Outcome
6-month GOSE ≤4 410(42.6) 147(61.8)
<.00016-month GOSE >4 386(40.1) 69(29.0)
DRS categories of disability - 1 month
0.02
0–1 (none/mild) 109(11.3) 16 (6.7)
2–6 (partial/moderate) 172(17.9) 50(21.0)
7–21(moderately severe/severe/extremely severe) 41(4.3) 13(5.5)
22–30 (vegetative/extreme vegetative/dead) 199(20.7) 75(31.5)
DRS categories of disability - 6 month
<.0001
0–1 (none/mild) 304(31.6) 47(19.7)
2–6 (partial/moderate) 221(23.0) 67(28.2)
7–21 (moderately severe/severe/extremely severe) 63(6.5) 24(10.1)
22–30 (vegetative/extreme vegetative/dead) 206(21.4) 78(32.8)
28-day survival 779(81.0) 172(72.3) 0.002
6 month survival 763(79.3) 162(68.1) <.0001
Ventilator-free days, (mean±SD) 19.4 ± 11.1 14.1 ± 10.6 <.0001
Total ICU days, (mean±SD) 7 ± 13 11 ± 10 <.0001








Abbreviations:; DRS, Disability Rating Score; GOSE, Extended Glasgow Outcome Score; ICU, intensive care unit; SD, standard deviation
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enlargement in patients with TBI. We did not observe
any evidence to support that hypertonic saline bolus
increases the risk of hematoma enlargement.
Our analysis has certain limitations that should be con-
sidered. The protocol for acquisition of serial CT scans
was not specified and variation can be expected within
institutions. Most likely, patients underwent CT scans
subsequent to a neurological deterioration. Changes in
serial CT scans may be detected in the absence of neuro-
logical deterioration [23]. However, previous studies
have not found any abnormalities on serial CT scans, in
the absence of neurological deterioration, that result in
therapeutic decisionmaking [24,25]. Therefore, the rate
of hematoma enlargement maybe underestimated in our
analysis. Most of such undetected enlargements, how-
ever, are probably asymptomatic and do not require any
therapeutic interventions. We did not use blinded or cen-
tral interpretation of CT scans to identify hematoma
enlargement and the ascertainment of hematoma
enlargement was made by study investigators. There-
fore, interobserver variation can be expected in identifi-
cation of hematoma enlargement. The rates of hema-
toma enlargement have been higher in studies that use
quantitative central analysis of CT scans in patients with
TBI [4]. While each site in the trial was encouraged to
implement resuscitation and critical care management
guidelines, previous studies have found variance
between institutions in compliance to such guidelines
[26]. The effect of such variations on our results is unde-
termined, although a differential compliance based on
presence or absence of hematoma enlargement is
unlikely.
Recombinant activated factor VII (rFVIIa) may prevent
hematoma enlargement in patients with TBI [27–29]. In
a prospective study of rFVIIa in TBI patients with intra-
cerebral hematoma, the rate of hematoma enlargement
was lower in rFVIIa-treated patients compared with that
seen in placebo-treated patients [29]. Therefore, the rate
of hematoma enlargement can be reduced with therapeu-
tic interventions in patients with TBI. The higher rate of
thromboembolic events associated with rFVIIa preven-
ted widespread use in patients with TBI [29,30]. The
results from 35 randomized clinical trials observed that
401 (9%) of 4468 subjects suffered thromboembolic
events (particularly arterial thromboembolic events)
associated with rFVIIa [31]. Our results suggest that
hematoma enlargement may be a direct contributor to
death and disability in patients with TBI at both 1 and 6
months. Future clinical trials must continue to evaluate
new therapeutic interventions aimed at reducing hema-
toma enlargement with a favorable risk benefit ratio in
patients with TBI.
Authors’ Disclosure Statement
No competing financial interests exist.
Acknowledgments
The manuscript was prepared using ROCHS_TBI
Research Materials obtained from the NHLBI Biologic
Specimen and Data Repository Information Coordinat-
ing Center and does not necessarily reflect the opinions
or views of the ROCHS_TBI or the NHLBI.
References
1. Homnick A, Sifri Z, Yonclas P, Mohr A, Livingston D. The tempo-
ral course of intracranial haemorrhage progression: How long is
observation necessary? Injury 2012;43:2122–2125.
2. Chang EF, Meeker M, Holland MC. Acute traumatic intraparenchy-
mal hemorrhage: Risk factors for progression in the early post-
injury period. Neurosurgery 2006;58:647–656.discussion 647–656
3. Oertel M, Kelly DF, McArthur D, Boscardin WJ, Glenn TC, Lee JH,
Gravori T, Obukhov D, McBride DQ, Martin NA. Progressive hem-
orrhage after head trauma: predictors and consequences of the
evolving injury. J Neurosurg 2002;96:109–116.
4. Narayan RK, Maas AI, Servadei F, Skolnick BE, Tillinger MN,
Marshall LF. Traumatic Intracerebral hemorrhage study G. Progres-
sion of traumatic intracerebral hemorrhage: a prospective observa-
tional study. J Neurotrauma 2008;25:629–639.
5. Jiang Y, Sun XC, Gui L, Tang WY, Zhen LP, Gu YJ, Wu HT. Lack
of association between apolipoprotein e promoters in epsilon4 carri-
ers and worsening on computed tomography in early stage of trau-
matic brain injury. Acta Neurochir Suppl 2008;105:233–236.
6. Moriya T, Tagami R, Furukawa M, Sakurai A, Kinoshita K, Tanjoh
K. A case of traumatic hematoma in the basal ganglia that showed
deterioration after arrival at the hospital. Acta Neurochir Suppl
2013;118:147–149.
7. Ding J, Yuan F, Guo Y, Chen SW, Gao WW, Wang G, Cao HL, Ju
SM, Chen H, Zhang PQ, Tian HL. A prospective clinical study of
routine repeat computed tomography (CT) after traumatic brain
injury (tbi). Brain Inj 2012;26:1211–1216.
8. Bulger EM, May S, Brasel KJ, Schreiber M, Kerby JD, Tisherman
SA, Newgard C, Slutsky A, Coimbra R, Emerson S, Minei JP, Bar-
darson B, Kudenchuk P, Baker A, Christenson J, Idris A, Davis D,
Fabian TC, Aufderheide TP, Callaway C, Williams C, Banek J, Vail-
lancourt C, van Heest R, Sopko G, Hata JS, Hoyt DB, Investigators
R.O.C. Out-of-hospital hypertonic resuscitation following severe
traumatic brain injury: a randomized controlled trial. JAMA
2010;304:1455–1464.
9. Weir J, Steyerberg EW, Butcher I, Lu J, Lingsma HF, McHugh GS,
Roozenbeek B, Maas AI, Murray GD. Does the extended glasgow
outcome scale add value to the conventional glasgow outcome
scale? J Neurotrauma 2012;29:53–58.
10. Chesnut RM. Early indicators of prognosis in severe traumatic
brian injury. 2014Oct 5;2014 https://www.braintrauma.org/pdf/
protected/prognosis_guidelines.pdf
11. Murray GD, Butcher I, McHugh GS, Lu J, Mushkudiani NA, Maas
AI, Marmarou A, Steyerberg EW. Multivariable prognostic analysis
in traumatic brain injury: results from the impact study. J Neuro-
trauma 2002;24:329–337.
12. Riley RD, Hayden JA, Steyerberg EW, Moons KG, Abrams K,
48
Journal of Vascular and Interventional N
eurology, Vol. 8
Kyzas PA, Malats N, Briggs A, Schroter S, Altman DG, Hemi-
ngway H, Group P. Prognosis research strategy (progress) 2: prog-
nostic factor research. PLoS Med 2013;10:e1001380.
13. Foreman BP, Caesar RR, Parks J, Madden C, Gentilello LM, Shafi
S, Carlile MC, Harper CR, Diaz-Arrastia RR. Usefulness of the
abbreviated injury score and the injury severity score in comparison
to the glasgow coma scale in predicting outcome after traumatic
brain injury. J Trauma 2007;62:946–950.
14. Lingsma H, Andriessen TM, Haitsema I, Horn J, van der Naalt J,
Franschman G, Maas AI, Vos PE, Steyerberg EW. Prognosis in
moderate and severe traumatic brain injury: External validation of
the impact models and the role of extracranial injuries. J Trauma
Acute Care Surg 2013;74:639–646.
15. Grote S, Bocker W, Mutschler W, Bouillon B, Lefering R. Diag-
nostic value of the glasgow coma scale for traumatic brain injury in
18,002 patients with severe multiple injuries. J Neurotrauma
2011;28:527–534.
16. Chieregato A, Fainardi E, Morselli-Labate AM, Antonelli V, Com-
pagnone C, Targa L, Kraus J, Servadei F. Factors associated with
neurological outcome and lesion progression in traumatic subarach-
noid hemorrhage patients. Neurosurgery 2005;56:671–680.discus-
sion 671–680
17. Roquilly A, Mahe PJ, Latte DD, Loutrel O, Champin P, Di Falco
C, Courbe A, Buffenoir K, Hamel O, Lejus C, Sebille V, Asehnoune
K. Continuous controlled-infusion of hypertonic saline solution in
traumatic brain-injured patients: a 9-year retrospective study. Crit
Care 2011;15:R260.
18. Baker AJ, Rhind SG, Morrison LJ, Black S, Crnko NT, Shek PN,
Rizoli SB. Resuscitation with hypertonic saline-dextran reduces
serum biomarker levels and correlates with outcome in severe trau-
matic brain injury patients. J Neurotrauma 2009;26:1227–1240.
19. Ziai WC, Toung TJ, Bhardwaj A. Hypertonic saline: First-line
therapy for cerebral edema? J Neurol Sci 2007;261:157–166.
20. Hartl R, Ghajar J, Hochleuthner H, Mauritz W. Hypertonic/hyper-
oncotic saline reliably reduces icp in severely head-injured patients
with intracranial hypertension. Acta Neurochir Suppl 1992;70:126–
129.
21. Wilder DM, Reid TJ, Bakaltcheva IB. Hypertonic resuscitation and
blood coagulation: in vitro comparison of several hypertonic solu-
tions for their action on platelets and plasma coagulation. Thromb
Res 2002;107:255–261.
22. Qureshi AI, Suarez JI. Use of hypertonic saline solutions in treat-
ment of cerebral edema and intracranial hypertension. Crit Care
Med 2000;28:3301–3313.
23. Thorson CM, Van Haren RM, Otero CA, Guarch GA, Curia E,
Barrera JM, Busko AM, Namias N, Bullock MR, Livingstone AS,
Proctor KG. Repeat head computed tomography after minimal brain
injury identifies the need for craniotomy in the absence of neuro-
logic change. J Trauma Acute Care Surg 2013;74:967–973.discus-
sion 973–965
24. Brown CV, Weng J, Oh D, Salim A, Kasotakis G, Demetriades D,
Velmahos GC, Rhee P. Does routine serial computed tomography of
the head influence management of traumatic brain injury? a pro-
spective evaluation. J Trauma 2004;57:939–943.
25. Sifri ZC, Homnick AT, Vaynman A, Lavery R, Liao W, Mohr A,
Hauser CJ, Manniker A, Livingston D. A prospective evaluation of
the value of repeat cranial computed tomography in patients with
minimal head injury and an intracranial bleed. J Trauma
2006;61:862–867.
26. Shafi S, Barnes SA, Millar D, Sobrino J, Kudyakov R, Berryman
C, Rayan N, Dubiel R, Coimbra R, Magnotti LJ, Vercruysse G,
Scherer LA, Jurkovich GJ, Nirula R. Suboptimal compliance with
evidence-based guidelines in patients with traumatic brain injuries. J
Neurosurg 2014;120:773–777.
27. White CE, Schrank AE, Baskin TW, Holcomb JB. Effects of
recombinant activated factor vii in traumatic nonsurgical intracranial
hemorrhage. Curr Surg 2006;63:310–317.
28. Zaaroor M, Soustiel JF, Brenner B, Bar-Lavie Y, Martinowitz U,
Levi L. Administration off label of recombinant factor-viia (rfviia)
to patients with blunt or penetrating brain injury without coagulop-
athy. Acta Neurochir (Wien) 2008;150:663–668.
29. Narayan RK, Maas AI, Marshall LF, Servadei F, Skolnick BE, Till-
inger MN. Recombinant factor viia in traumatic intracerebral hem-
orrhage: results of a dose-escalation clinical trial. Neurosurgery
2008;62:776–786.discussion 786–778
30. Brophy GM, Candeloro CL, Robles JR, Brophy DF. Recombinant
activated factor vii use in critically ill patients: Clinical outcomes
and thromboembolic events. Ann Pharmacother 2013;47:447–454.
31. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant
activated factor vii in randomized clinical trials. N Engl J Med
2010;363:1791–1800.
Qureshi et al. 49
Journal of Vascular and Interventional N
eurology, Vol. 8
